Forum Kamdar1, Satyabrata Das2, Wuming Gong2, André Klaassen Kamdar2, Tatyana A Meyers3, Pruthvi Shah2, James M Ervasti4, DeWayne Townsend5, Timothy J Kamp6, Joseph C Wu7, Mary G Garry1, Jianyi Zhang8, Daniel J Garry9. 1. Lillehei Heart Institute, Cardiovascular Division, University of Minnesota, Minneapolis, Minnesota; Paul and Sheila Muscular Dystrophy Center, University of Minnesota, Minneapolis, Minnesota. 2. Lillehei Heart Institute, Cardiovascular Division, University of Minnesota, Minneapolis, Minnesota. 3. Department of Integrative Biology and Physiology, University of Minnesota, Minneapolis, Minnesota. 4. Paul and Sheila Muscular Dystrophy Center, University of Minnesota, Minneapolis, Minnesota; Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, Minnesota. 5. Lillehei Heart Institute, Cardiovascular Division, University of Minnesota, Minneapolis, Minnesota; Paul and Sheila Muscular Dystrophy Center, University of Minnesota, Minneapolis, Minnesota; Department of Integrative Biology and Physiology, University of Minnesota, Minneapolis, Minnesota. 6. Cardiovascular Medicine, University of Wisconsin-Madison, Madison, Wisconsin. 7. Stanford Cardiovascular Institute, Stanford University, Palo Alto, California. 8. Department of Biomedical Engineering, University of Alabama at Birmingham, Birmingham, Alabama. 9. Lillehei Heart Institute, Cardiovascular Division, University of Minnesota, Minneapolis, Minnesota; Paul and Sheila Muscular Dystrophy Center, University of Minnesota, Minneapolis, Minnesota; Department of Integrative Biology and Physiology, University of Minnesota, Minneapolis, Minnesota; Stem Cell Institute, University of Minnesota, Minneapolis, Minnesota. Electronic address: garry@umn.edu.
Abstract
BACKGROUND: Although cardiomyopathy has emerged as a leading cause of death in Duchenne muscular dystrophy (DMD), limited studies and therapies have emerged for dystrophic heart failure. OBJECTIVES: The purpose of this study was to model DMD cardiomyopathy using DMD patient-specific human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes and to identify physiological changes and future drug therapies. METHODS: To explore and define therapies for DMD cardiomyopathy, the authors used DMD patient-specific hiPSC-derived cardiomyocytes to examine the physiological response to adrenergic agonists and β-blocker treatment. The authors further examined these agents in vivo using wild-type and mdx mouse models. RESULTS: At baseline and following adrenergic stimulation, DMD hiPSC-derived cardiomyocytes had a significant increase in arrhythmic calcium traces compared to isogenic controls. Furthermore, these arrhythmias were significantly decreased with propranolol treatment. Using telemetry monitoring, the authors observed that mdx mice, which lack dystrophin, had an arrhythmic death when stimulated with isoproterenol; the lethal arrhythmias were rescued, in part, by propranolol pre-treatment. Using single-cell and bulk RNA sequencing (RNA-seq), the authors compared DMD and control hiPSC-derived cardiomyocytes, mdx mice, and control mice (in the presence or absence of propranolol and isoproterenol) and defined pathways that were perturbed under baseline conditions and pathways that were normalized after propranolol treatment in the mdx model. The authors also undertook transcriptome analysis of human DMD left ventricle samples and found that DMD hiPSC-derived cardiomyocytes have dysregulated pathways similar to the human DMD heart. The authors further determined that relatively few patients with DMD see a cardiovascular specialist or receive β-blocker therapy. CONCLUSIONS: The results highlight mechanisms and therapeutic interventions from human to animal and back to human in the dystrophic heart. These results may serve as a prelude for an adequately powered clinical study that examines the impact of β-blocker therapy in patients with dystrophinopathies.
BACKGROUND: Although cardiomyopathy has emerged as a leading cause of death in Duchenne muscular dystrophy (DMD), limited studies and therapies have emerged for dystrophic heart failure. OBJECTIVES: The purpose of this study was to model DMD cardiomyopathy using DMD patient-specific human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes and to identify physiological changes and future drug therapies. METHODS: To explore and define therapies for DMD cardiomyopathy, the authors used DMD patient-specific hiPSC-derived cardiomyocytes to examine the physiological response to adrenergic agonists and β-blocker treatment. The authors further examined these agents in vivo using wild-type and mdx mouse models. RESULTS: At baseline and following adrenergic stimulation, DMD hiPSC-derived cardiomyocytes had a significant increase in arrhythmic calcium traces compared to isogenic controls. Furthermore, these arrhythmias were significantly decreased with propranolol treatment. Using telemetry monitoring, the authors observed that mdx mice, which lack dystrophin, had an arrhythmic death when stimulated with isoproterenol; the lethal arrhythmias were rescued, in part, by propranolol pre-treatment. Using single-cell and bulk RNA sequencing (RNA-seq), the authors compared DMD and control hiPSC-derived cardiomyocytes, mdx mice, and control mice (in the presence or absence of propranolol and isoproterenol) and defined pathways that were perturbed under baseline conditions and pathways that were normalized after propranolol treatment in the mdx model. The authors also undertook transcriptome analysis of human DMD left ventricle samples and found that DMD hiPSC-derived cardiomyocytes have dysregulated pathways similar to the human DMD heart. The authors further determined that relatively few patients with DMD see a cardiovascular specialist or receive β-blocker therapy. CONCLUSIONS: The results highlight mechanisms and therapeutic interventions from human to animal and back to human in the dystrophic heart. These results may serve as a prelude for an adequately powered clinical study that examines the impact of β-blocker therapy in patients with dystrophinopathies.
Authors: Forum Kamdar; Andre Klaassen Kamdar; Naoko Koyano-Nakagawa; Mary G Garry; Daniel J Garry Journal: J Card Fail Date: 2015-04-28 Impact factor: 5.712
Authors: C Ian Spencer; Shiro Baba; Kenta Nakamura; Ethan A Hua; Marie A F Sears; Chi-cheng Fu; Jianhua Zhang; Sadguna Balijepalli; Kiichiro Tomoda; Yohei Hayashi; Paweena Lizarraga; Julianne Wojciak; Melvin M Scheinman; Katriina Aalto-Setälä; Jonathan C Makielski; Craig T January; Kevin E Healy; Timothy J Kamp; Shinya Yamanaka; Bruce R Conklin Journal: Stem Cell Reports Date: 2014-07-04 Impact factor: 7.765
Authors: Matteo Vatta; Bhagyalaxmi Mohapatra; Shinawe Jimenez; Ximena Sanchez; Georgine Faulkner; Zeev Perles; Gianfranco Sinagra; Jiuann-Huey Lin; Thuy M Vu; Qiang Zhou; Karla R Bowles; Andrea Di Lenarda; Lisa Schimmenti; Michelle Fox; Michelle A Chrisco; Ross T Murphy; William McKenna; Perry Elliott; Neil E Bowles; Ju Chen; Giorgio Valle; Jeffrey A Towbin Journal: J Am Coll Cardiol Date: 2003-12-03 Impact factor: 24.094
Authors: Francesco Chemello; Zhaoning Wang; Hui Li; John R McAnally; Ning Liu; Rhonda Bassel-Duby; Eric N Olson Journal: Proc Natl Acad Sci U S A Date: 2020-11-04 Impact factor: 11.205
Authors: Ayhan Atmanli; Andreas C Chai; Miao Cui; Zhaoning Wang; Takahiko Nishiyama; Rhonda Bassel-Duby; Eric N Olson Journal: Circ Res Date: 2021-08-10 Impact factor: 23.213
Authors: Melanie Gartz; Margaret Beatka; Mariah J Prom; Jennifer L Strande; Michael W Lawlor Journal: Hum Mol Genet Date: 2021-11-16 Impact factor: 5.121